Skip to main content

Drug Interactions between Adderall and nilotinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

amphetamine nilotinib

Applies to: Adderall (amphetamine / dextroamphetamine) and nilotinib

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations as well as the pharmacologic and adverse effects of amphetamines. The proposed mechanism involves the inhibition of CYP450 2D6, an isoenzyme partially responsible for the metabolic clearance of certain amphetamines. Furthermore, because CYP450 2D6 is genetically polymorphic, variations in amphetamine metabolism across populations may either increase or decrease the risk associated with this interaction. Increased exposure to amphetamines may potentiate the risk of serious adverse reactions such as serotonin syndrome, seizures, psychiatric adverse reactions (e.g., new psychotic or manic symptoms), peripheral vasculopathy (including Raynaud's Phenomenon), and cardiovascular effects (e.g., hypertension, tachycardia). However, data evaluating the interaction are not available.

MANAGEMENT: Caution and closer monitoring for adverse effects are recommended when amphetamines are used concurrently with CYP450 2D6 inhibitors, and a reduction in the initial amphetamine dose should be considered. Patients should be more closely monitored for signs and symptoms of serotonin syndrome, particularly during the initiation of amphetamine therapy and following any dosage increases. Additional caution is advised when amphetamines are coadministered with CYP450 2D6 inhibitors that lower the seizure threshold (e.g., bupropion). Patients should be instructed to notify their healthcare provider if they experience increased amphetamine-related side effects, such as seizures, cardiovascular effects (e.g., hypertension, tachycardia), or symptoms of serotonin syndrome (e.g., mental status changes, autonomic dysfunction like tachycardia or hyperthermia, neuromuscular abnormalities such as hyperreflexia, or gastrointestinal symptoms).

References (14)
  1. (2023) "Product Information. Amphetamine Sulfate (amphetamine)." Granules Pharmaceuticals Inc.
  2. (2024) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." Actavis (formerly Abrika Pharmaceuticals LLP)
  3. (2023) "Product Information. Dexamfetamine (dexamfetamine)." Rosemont Pharmaceuticals Ltd
  4. (2024) "Product Information. Dexamfetamine (Aspen) (dexamfetamine)." Aspen Pharma Pty Ltd
  5. (2018) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." AA Pharma Inc
  6. (2023) "Product Information. Methamphetamine Hydrochloride (methamphetamine)." Mayne Pharma Inc
  7. (2023) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Alvogen Inc
  8. (2024) "Product Information. Teva-Lisdexamfetamine (lisdexamfetamine)." Teva Canada Limited
  9. (2024) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Takeda UK Ltd
  10. (2024) "Product Information. Vyvanse (lisdexamfetamine)." Takeda Pharmaceuticals Australia Pty Ltd
  11. (2024) "Product Information. Zyban SR (bupropion)." GlaxoSmithKline Australia Pty Ltd
  12. (2024) "Product Information. Zyban (bupropion)." GlaxoSmithKline UK Ltd
  13. (2021) "Product Information. Teva-Bupropion XL (bupropion)." Teva Canada Limited
  14. (2023) "Product Information. BuPROPion Hydrochloride XL (buPROPion)." Camber Pharmaceuticals, Inc
Moderate

dextroamphetamine nilotinib

Applies to: Adderall (amphetamine / dextroamphetamine) and nilotinib

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations as well as the pharmacologic and adverse effects of amphetamines. The proposed mechanism involves the inhibition of CYP450 2D6, an isoenzyme partially responsible for the metabolic clearance of certain amphetamines. Furthermore, because CYP450 2D6 is genetically polymorphic, variations in amphetamine metabolism across populations may either increase or decrease the risk associated with this interaction. Increased exposure to amphetamines may potentiate the risk of serious adverse reactions such as serotonin syndrome, seizures, psychiatric adverse reactions (e.g., new psychotic or manic symptoms), peripheral vasculopathy (including Raynaud's Phenomenon), and cardiovascular effects (e.g., hypertension, tachycardia). However, data evaluating the interaction are not available.

MANAGEMENT: Caution and closer monitoring for adverse effects are recommended when amphetamines are used concurrently with CYP450 2D6 inhibitors, and a reduction in the initial amphetamine dose should be considered. Patients should be more closely monitored for signs and symptoms of serotonin syndrome, particularly during the initiation of amphetamine therapy and following any dosage increases. Additional caution is advised when amphetamines are coadministered with CYP450 2D6 inhibitors that lower the seizure threshold (e.g., bupropion). Patients should be instructed to notify their healthcare provider if they experience increased amphetamine-related side effects, such as seizures, cardiovascular effects (e.g., hypertension, tachycardia), or symptoms of serotonin syndrome (e.g., mental status changes, autonomic dysfunction like tachycardia or hyperthermia, neuromuscular abnormalities such as hyperreflexia, or gastrointestinal symptoms).

References (14)
  1. (2023) "Product Information. Amphetamine Sulfate (amphetamine)." Granules Pharmaceuticals Inc.
  2. (2024) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." Actavis (formerly Abrika Pharmaceuticals LLP)
  3. (2023) "Product Information. Dexamfetamine (dexamfetamine)." Rosemont Pharmaceuticals Ltd
  4. (2024) "Product Information. Dexamfetamine (Aspen) (dexamfetamine)." Aspen Pharma Pty Ltd
  5. (2018) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." AA Pharma Inc
  6. (2023) "Product Information. Methamphetamine Hydrochloride (methamphetamine)." Mayne Pharma Inc
  7. (2023) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Alvogen Inc
  8. (2024) "Product Information. Teva-Lisdexamfetamine (lisdexamfetamine)." Teva Canada Limited
  9. (2024) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Takeda UK Ltd
  10. (2024) "Product Information. Vyvanse (lisdexamfetamine)." Takeda Pharmaceuticals Australia Pty Ltd
  11. (2024) "Product Information. Zyban SR (bupropion)." GlaxoSmithKline Australia Pty Ltd
  12. (2024) "Product Information. Zyban (bupropion)." GlaxoSmithKline UK Ltd
  13. (2021) "Product Information. Teva-Bupropion XL (bupropion)." Teva Canada Limited
  14. (2023) "Product Information. BuPROPion Hydrochloride XL (buPROPion)." Camber Pharmaceuticals, Inc

Drug and food interactions

Major

nilotinib food

Applies to: nilotinib

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of nilotinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.

ADJUST DOSING INTERVAL: Food increases the oral bioavailability of nilotinib. The mechanism of interaction is unknown. Compared to the fast state, nilotinib systemic exposure (AUC) increased by 82% when the dose was given 30 minutes after a high-fat meal. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.

MANAGEMENT: Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.

References (1)
  1. (2007) "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals
Moderate

amphetamine food

Applies to: Adderall (amphetamine / dextroamphetamine)

GENERALLY AVOID: Alcohol may potentiate the cardiovascular effects of amphetamines. The exact mechanism of interaction is unknown. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state. The interaction was suspected in a case report of a 20-year-old male who experienced retrosternal chest pain shortly after drinking alcohol and taking a double dose of his amphetamine/dextroamphetamine medication (Adderall 15 mg X 2) to stay alert. The patient had no family history of cardiovascular diseases, and his past medical history was remarkable only for ADHD. Prior to the episode, the patient had not taken his medication for weeks and had been drinking whiskey the previous three nights before going to bed. The patient was diagnosed with myocardial infarction likely secondary to amphetamine-induced coronary vasospasm.

MANAGEMENT: Concomitant use of amphetamines and alcohol should be avoided if possible, especially in patients with a history of heart disease.

References (2)
  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M (2009) "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med, 22, p. 197-201
Moderate

dextroamphetamine food

Applies to: Adderall (amphetamine / dextroamphetamine)

GENERALLY AVOID: Alcohol may potentiate the cardiovascular effects of amphetamines. The exact mechanism of interaction is unknown. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state. The interaction was suspected in a case report of a 20-year-old male who experienced retrosternal chest pain shortly after drinking alcohol and taking a double dose of his amphetamine/dextroamphetamine medication (Adderall 15 mg X 2) to stay alert. The patient had no family history of cardiovascular diseases, and his past medical history was remarkable only for ADHD. Prior to the episode, the patient had not taken his medication for weeks and had been drinking whiskey the previous three nights before going to bed. The patient was diagnosed with myocardial infarction likely secondary to amphetamine-induced coronary vasospasm.

MANAGEMENT: Concomitant use of amphetamines and alcohol should be avoided if possible, especially in patients with a history of heart disease.

References (2)
  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M (2009) "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med, 22, p. 197-201

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.